Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Current Deferred Revenue (2021 - 2023)

Pulse Biosciences (PLSE) has 3 years of Current Deferred Revenue data on record, last reported at $4000.0 in Q1 2023.

  • For Q1 2023, Current Deferred Revenue fell 75.0% year-over-year to $4000.0; the TTM value through Mar 2023 reached $4000.0, down 75.0%, while the annual FY2021 figure was $16000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $4000.0 in Q1 2023 per PLSE's latest filing, down from $38000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $38000.0 in Q3 2022 and bottomed at $4000.0 in Q1 2023.
  • Average Current Deferred Revenue over 3 years is $18833.3, with a median of $16000.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 442.86% in 2022, then plummeted 75.0% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $16000.0 in 2021, then surged by 137.5% to $38000.0 in 2022, then plummeted by 89.47% to $4000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $4000.0 in Q1 2023, $38000.0 in Q3 2022, and $32000.0 in Q2 2022.